HOME >> MEDICINE >> NEWS
Disulfiram and cognitive behavioral therapy appear effective for treating cocaine dependence

CHICAGO Disulfiram (a drug used to help selected patients with alcohol disorders remain sober) and cognitive behavioral therapy appear effective in reducing cocaine use, especially among cocaine users who are not dependent on alcohol, according to an article in the March issue of The Archives of General Psychiatry, one of the JAMA/Archives journals.

Patients taking disulfiram who ingest even small amounts of alcohol develop a reaction that produces nausea, flushing, vomiting, and throbbing headache. At times, this reaction can be severe and can lead to critical illness, such as severe respiratory problems, circulatory problems, or even death. According to the article, alcohol is a powerful "cue" for using cocaine, and can impair judgment and lower resistance to cravings for cocaine. Researchers hypothesize that by reducing alcohol use with disulfiram, users might be less likely to abuse cocaine. However, use of disulfiram has not been evaluated in general populations of cocaine users.

Kathleen M. Carroll, Ph.D., from Yale University School of Medicine, New Haven, Conn., and colleagues randomly assigned 121 cocaine-dependent adults (average age, 34.6 years) to receive either disulfiram or placebo over a 12-week period. Participants were also randomized to participate in either cognitive behavioral therapy (CBT) or interpersonal psychotherapy (IPT, a less structured form of behavioral therapy).

"Participants assigned to disulfiram reduced their cocaine use significantly more than those assigned to placebo, and those assigned to CBT reduced their cocaine use significantly more than those assigned to IPT," the authors found. The benefits of disulfiram and CBT were most pronounced in participants who were not alcohol-dependent and who did not drink during the study.

The authors write, "This is the first placebo-controlled trial, to our knowledge, to demonstrate that disulfiram therapy is effective in nonalcoholic cocaine-dependent o
'"/>

Contact: Jacqueline Weaver
203-432-8555
JAMA and Archives Journals
1-Mar-2004


Page: 1 2

Related medicine news :

1. Boston University team finds link between high cholesterol and better cognitive performance
2. Binge drinking can impair both mood and cognitive performance
3. Nonhuman primate males more susceptible to age-related cognitive decline than females
4. Smoking causes cognitive impairment in adolescents
5. Maintaining physical activity linked to less cognitive decline in older men
6. Metabolic syndrome associated with cognitive decline in elderly persons
7. Study reveals link between cardiovascular risk and cognitive decline
8. Yale to study marijuana, ecstasy and teen cognitive deficits
9. Elderly experience long-term cognitive decline after surgery
10. High blood pressure related decline in cognitive function affects adults young and old
11. Trials launched to test treatment of cognitive dysfunction in schizophrenia

Post Your Comments:
(Date:4/1/2015)... Peoria, Ill. (PRWEB) April 01, 2015 ... the OSF Healthcare System , was welcomed into ... Dedication Ceremony officiated by Msgr. Paul E. Showalter, vicar ... , The Blessing and Dedication culminated a nearly year-long ... the eleventh OSF HealthCare hospital. Speakers for the morning ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 ... senior care, today announces the launch of the ... innovative senior care stakeholders and technology companies. The announcement ... Center (NIC) Capital and Business Strategies Forum in ... members, the new Alliance program is now open for ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , Dallas ... Department of Plastic Surgery at UT Southwestern Medical Center, ... blindness resulting from the use of facial aesthetic ... study, along with ideas for treatment and prevention in ... to see increasing reports of blindness as a result ...
(Date:4/1/2015)... GA (PRWEB) April 01, 2015 ... Medicine Practice, Pediatric Emergency Medicine Practice, and Hospital ... has partnered with AgileMD to provide the content ... , in a mobile application format available on ... , “Our collaboration with AgileMD to develop mobile ...
(Date:4/1/2015)... 2015 Skin cancer is one of the ... caught early. Forefront Dermatology and Dermatology Associates of Wisconsin want ... before it spreads so they are hosting a free skin ... 8:30am - 12:30pm. , “If we can see the ... concern, that could become cancerous,” said Dr. Ken Katz, who ...
Breaking Medicine News(10 mins):Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3Health News:Forefront Dermatology and Dermatology Associates of Wisconsin Offers Skin Cancer Screenings on April 11th 2
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kz78wm/medical_device ) ... Device Studies: Clinical Evidence" conference to their ... specifically for those who are involved in gathering ... diagnostic products. Clinical data is required for all ... appropriate clinical evidence has grown substantially in the ...
(Date:4/1/2015)... Md. , April 1, 2015  RegeneRx ... today announced that a new medical paper has ... beta 4 (TB4) in patients with severe dry ... the study and the physicians stated that statistically ... severe dry eye were seen at various time ...
(Date:4/1/2015)... LAVAL, Quebec , April 1, ... Inc. (NYSE: VRX and ... completed the previously announced acquisition of ... a specialty pharmaceutical company that offers ...  (rifaximin) 550 mg, RUCONEST ®  (C1 esterase inhibitor ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
Cached News: